MGK: Thanks for another provocative post updating your interpretations and educated guesses on management's evolving priorities as it seeks to fulfill Leronlimab's potential. While this latest post also took a while to read, I think it's worth noting that it obviously took much longer for you to organize and compose it -- so thanks again for the time and effort.

As to the partner options you pose in closing, I'm sticking with ohm's analysis that the good results from the MD Anderson mouse study were likely exclusively LL based, which would support your NIH educated guess. Had the 2022 study results showed synergy between LL and Keytruda, it's hard for me to imagine that MRK's management would have been sitting on its hands these last 2 years. However, I'm guessing that it's also possible that MRK management has recently communicated to CYDY an interest in LL independent of Keytruda, or, more precisely, as a future replacement for Keytruda. Then again, with Dr Jay's NIH contacts, your NIH guess does make more sense.